Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
Sponsor: GlaxoSmithKline
Summary
This is a multi-center, randomized, two-part (Part A and Part B) study investigating the safety and efficacy of efimosfermin alfa in adult participants with compensated cirrhosis due to MASH. Participants who complete the treatment during Part A of the study and meet the inclusion criteria will have the option to enroll in Part B (open label) of the study.
Official title: A Phase 3, Two-part, Double-blind, Randomized, Placebo-controlled Study to Investigate the Safety and Efficacy of Efimosfermin Alfa Injection in Adult Participants With Compensated Cirrhosis (Stage F4 Fibrosis) Due to Metabolic Dysfunction-associated Steatohepatitis (NEBULA-2)
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
380
Start Date
2026-07-22
Completion Date
2033-12-08
Last Updated
2026-08-05
Healthy Volunteers
No
Interventions
Efimosfermin alfa
Efimosfermin alfa (subcutaneous injection) will be administered.
Placebo
Placebo (subcutaneous injection) will be administered.
Locations (2)
GSK Investigational Site
Miami, Florida, United States
GSK Investigational Site
Houston, Texas, United States